THE CHEMOSEROTHERAPY OF EXPERIMENTAL PNEUMOCOCCAL INFECTION

1. A single small dose of ethylhydrocuprein (optochin base), which by itself has practically no protective effect against experimental pneumococcal infection in mice, is capable of increasing the threshold value of the type homologous antipneumococcus serum at least fifty times. 2. This effect is pr...

Descripción completa

Detalles Bibliográficos
Autor principal: Moore, Henry F.
Formato: Texto
Lenguaje:English
Publicado: The Rockefeller University Press 1915
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2125358/
https://www.ncbi.nlm.nih.gov/pubmed/19867924
_version_ 1782141877958475776
author Moore, Henry F.
author_facet Moore, Henry F.
author_sort Moore, Henry F.
collection PubMed
description 1. A single small dose of ethylhydrocuprein (optochin base), which by itself has practically no protective effect against experimental pneumococcal infection in mice, is capable of increasing the threshold value of the type homologous antipneumococcus serum at least fifty times. 2. This effect is proportionately many times greater than a simple summation of the protective effects of these two bodies. 3. No such effect is obtained when the antiserum used is one produced against a strain of pneumococcus from a group other than that to which the infecting pneumococcus belongs.
format Text
id pubmed-2125358
institution National Center for Biotechnology Information
language English
publishDate 1915
publisher The Rockefeller University Press
record_format MEDLINE/PubMed
spelling pubmed-21253582008-04-18 THE CHEMOSEROTHERAPY OF EXPERIMENTAL PNEUMOCOCCAL INFECTION Moore, Henry F. J Exp Med Article 1. A single small dose of ethylhydrocuprein (optochin base), which by itself has practically no protective effect against experimental pneumococcal infection in mice, is capable of increasing the threshold value of the type homologous antipneumococcus serum at least fifty times. 2. This effect is proportionately many times greater than a simple summation of the protective effects of these two bodies. 3. No such effect is obtained when the antiserum used is one produced against a strain of pneumococcus from a group other than that to which the infecting pneumococcus belongs. The Rockefeller University Press 1915-10-01 /pmc/articles/PMC2125358/ /pubmed/19867924 Text en Copyright © Copyright, 1915, by The Rockefeller Institute for Medical Research New York This article is distributed under the terms of an Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months after the publication date (see http://www.rupress.org/terms). After six months it is available under a Creative Commons License (Attribution–Noncommercial–Share Alike 4.0 Unported license, as described at http://creativecommons.org/licenses/by-nc-sa/4.0/).
spellingShingle Article
Moore, Henry F.
THE CHEMOSEROTHERAPY OF EXPERIMENTAL PNEUMOCOCCAL INFECTION
title THE CHEMOSEROTHERAPY OF EXPERIMENTAL PNEUMOCOCCAL INFECTION
title_full THE CHEMOSEROTHERAPY OF EXPERIMENTAL PNEUMOCOCCAL INFECTION
title_fullStr THE CHEMOSEROTHERAPY OF EXPERIMENTAL PNEUMOCOCCAL INFECTION
title_full_unstemmed THE CHEMOSEROTHERAPY OF EXPERIMENTAL PNEUMOCOCCAL INFECTION
title_short THE CHEMOSEROTHERAPY OF EXPERIMENTAL PNEUMOCOCCAL INFECTION
title_sort chemoserotherapy of experimental pneumococcal infection
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2125358/
https://www.ncbi.nlm.nih.gov/pubmed/19867924
work_keys_str_mv AT moorehenryf thechemoserotherapyofexperimentalpneumococcalinfection
AT moorehenryf chemoserotherapyofexperimentalpneumococcalinfection

Ejemplares similares